- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03719027
Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH) (Preva-CTEPH)
Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism. History of the Diagnosis. (Preva-CTEPH) Study
The prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE) varies widely (0.4% to 8.8%) in the literature. This large variation could be due to the inclusion of patients with pre-existing CTEPH revealed on the occasion of a recurrence of PE. However, the absence of hemodynamic data when diagnosing PE does not allow to distinguish these patients. A prospective multicentric study involving 146 patients showed that the majority of patients with CTEPH during follow-up had a pulmonary hypertension unknown at the time of PE diagnosis. It is necessary to confirm these results in a broader study.
The aim of this study is to evaluate the cumulative incidence of CTEPH after a PE.
Study Overview
Status
Intervention / Treatment
Detailed Description
The patients selected in this study are patients with an objectively confirmed PE and previously included since at least 12 months in one of the studies of the INNOVTE network.
Patients who are alive at the time of the selection for the PREVA-CTEPH study are contacted by phone or by mail for inclusion in the prospective interventional part of the PREVA-CTEPH study. Patients who consent to participate to this prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH. Patients with dyspnea (NYHA >1) and/or a high or intermediate echocardiographic probability of pulmonary hypertension (ESC criteria) have a V/Q lung scan, a right heart catheterization and a pulmonary angiography to objectively confirm the diagnosis of CTEPH according to the current ESC guidelines.
Retrospective phase: All clinical (dyspnea, signs of right ventricular insufficiency...), echocardiographic and imaging (pulmonary angiography, V/Q lung scan) relevant data after the diagnosis of index PE are retrieved from the clinical chart of each patients alive at the time of the selection for the PREVA-CTEPH study and/or with a diagnosis of CTEPH confirmed after the diagnosis of index PE and/or if the patient don't consent to participate to the prospective interventional phase.
For patients died between the inclusion in one of the studies of the INNOVTE network and the time of the selection for the PREVA-CTEPH study, the date and the cause of death are recorded. The same data of the retrospective phase are retrieved.
All cases of CTEPH are adjudicated by an independent committee. In this case, initial Imaging data (CT pulmonary angiography and echocardiography) performed at the time of index PE diagnosis are retrieved for searching previous sign of CTEPH.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Olivier SANCHEZ, MD, PhD
- Phone Number: +33156093487
- Email: olivier.sanchez@aphp.fr
Study Locations
-
-
-
Besançon, France
- Recruiting
- CHU Jean Minjoz
-
Contact:
- Nicolas MENEVEAU, MD,PhD
-
Brest, France
- Recruiting
- La Cavale Blanche
-
Contact:
- Francis Couturaud, MD,PhD
-
Paris, France, 75015
- Recruiting
- Hopital Europeen Georges-Pompidou
-
Contact:
- Olivier Sanchez, MD,PhD
- Phone Number: +33156093487
- Email: olivier.sanchez@aphp.fr
-
Saint-Étienne, France
- Recruiting
- Hôpital Nord
-
Contact:
- Laurent BERTOLETTI, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 18 years
- Pulmonary embolism objectively confirmed
- Treated during at least 3 months with curative anticoagulant
- Previously included since at least 1 year in one of the studies of the INNOVTE network
- affiliated to the national social security
- after written informed consent
Exclusion Criteria:
- Patients with an objectively confirmed CTEPH before the diagnosis of index PE
- Follow-up impossible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study population
Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
|
Dyspnea assessment (NYHA functional class) EKG Echocardiography
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulated incidence of CTEPH
Time Frame: 30-day +/- 15 days after inclusion visit
|
Cumulated incidence rate of CTEPH after pulmonary embolism
|
30-day +/- 15 days after inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulated incidence of CTEPH in patients without previous signs of CTEPH at the time of index PE diagnosis
Time Frame: 30-day +/- 15 days after inclusion visit
|
Cumulated incidence rate of CTEPH in patients without previous signs of CTEPH at the time of index PE diagnosis
|
30-day +/- 15 days after inclusion visit
|
Cumulated incidence of CTEPH in patients with previous signs of CTEPH at the time of index PE diagnosis
Time Frame: 30-day +/- 15 days after inclusion visit
|
Cumulated incidence rate of CTEPH in patients with previous signs of CTEPH at the time of index PE diagnosis
|
30-day +/- 15 days after inclusion visit
|
Risk factors of CTEPH
Time Frame: 30-day +/- 15 days after inclusion visit
|
Hazard ratio of risk factors independently and significantly associated with the diagnosis of CTEPH after pulmonary embolism
|
30-day +/- 15 days after inclusion visit
|
Complications associated with right heart catheterization
Time Frame: 30-day +/- 15 days after inclusion visit
|
Complication rate of right heart catheterization
|
30-day +/- 15 days after inclusion visit
|
Complications associated with pulmonary angiography
Time Frame: 30-day +/- 15 days after inclusion visit
|
Complication rate of pulmonary angiography
|
30-day +/- 15 days after inclusion visit
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Olivier SANCHEZ, MD, PhD, Université Paris Descartes
Publications and helpful links
General Publications
- Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, Pontal D, Guegan M, Simonneau G, Meyer G, Sanchez O. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost. 2014 Sep 2;112(3):598-605. doi: 10.1160/TH13-07-0538. Epub 2014 Jun 5.
- Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT, Huisman MV, Klok FA. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017 Feb 23;49(2):1601792. doi: 10.1183/13993003.01792-2016. Print 2017 Feb.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K161203J
- 2017-A02047-46 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
GlaxoSmithKlineCompleted
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
Clinical Trials on Study population
-
Centre Hospitalier Universitaire de BesanconTerminatedPostoperative; Dysfunction Following Cardiac Surgery | Transfusion Related ComplicationFrance
-
University Medical Centre LjubljanaRecruitingHelicobacter Pylori Infection | TransmissionSlovenia
-
Seoul National University HospitalCompletedSagging Eyelid Skin
-
Assistance Publique - Hôpitaux de ParisAgence Nationale de Recherche (ANR) National Research AgencyCompletedMental Disorder, ChildFrance
-
Washington University School of MedicineCompletedSingle Ventricle Fontan PalliationUnited States
-
Columbia UniversityAllerganCompletedBrittle NailsUnited States
-
Todos Medical, Ltd.Unknown
-
M.D. Anderson Cancer CenterActive, not recruitingPediatric CancerUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingVaccinationsUnited States
-
University College, LondonUnknownDementia, Alzheimer, Electronic Health Records, Hospitalizations, Epidemiology, Comorbidity, United Kingdom, Incidence, Mortality, Cause of Death